Results from the phase 2b PROCEED trial of intravenous bocunebart (also known as Lu AG09222) showed that the drug was able to ...
Shares in BridgeBio were ticking up today after it revealed data from its phase 3 trial of infigratinib in achondroplasia, ...
In understanding what makes the patient voice so essential to successful drug development, let’s take a critical eye to what ...
EVERSANA, a leading provider of commercialisation services to the global life sciences industry, has named Monica Avram as ...
Roche has revealed the data behind a positive phase 3 trial for its oral BTK inhibitor fenebrutinib in primary progressive ...
In its main clinical trial, mRNA-1010 was shown to be 26.6% more effective than the comparator flu shot in adults aged 50 ...
Behind every drug and drug candidate are stories – human stories as well as scientific stories. In this interview from the sidelines of the Biotech Showcase in San Francisco last month, Alexander ...
The 466,000 sq ft centre will serve as a hub to join Novartis' current R&D sites in Cambridge, Massachusetts, and Basel, ...
Eli Lilly has signed its second pipeline-building deal in two days, reaching an agreement to buy in vivo CAR-T developer Orna ...
Incubated by Flagship Pioneering, Generate applies AI to teasing out the three-dimensional structure of human proteins, ...
"The government has claimed that the deal will only cost around £1 billion per year, but the UK's new commitment to double ...
Hunter syndrome, also known as mucopolysaccharidosis type II (MPS II), is a rare, X-linked recessive genetic disease caused by a deficiency in the enzyme iduronate-2-sulfatase that can lead to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results